Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Neuracle Science Co. Ltd. has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 3 examiners and 3 art units, indicating distinct examination channels across the active docket.
CHERNYSHEV, OLGA N is the busiest examiner, with 1 pending matter. The even distribution supports application-specific monitoring and technical response preparation.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| No statute on record | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHERNYSHEV, OLGA N | 1 | 54.5% | +34.0% |
| LEE, JIA-HAI | 1 | 49.0% | +46.9% |
| SANG, HONG | 1 | 54.9% | +62.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18776405 | USE OF ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A5 ANTIBODIES FOR THE TREATMENT AND DIAGNOSIS OF MOOD DISORDERS | CHERNYSHEV, OLGA N | 28d overdue |
| 18158259 | USE OF ANTI-FAM19A5 ANTIBODIES FOR TREATING CANCERS | SANG, HONG | 46d |
| 18552281 | POLYPEPTIDE INHIBITORS AND USES THEREOF | LEE, JIA-HAI | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| 1658 | 1 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18776405 | USE OF ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A5 ANTIBODIES FOR THE TREATMENT AND DIAGNOSIS OF MOOD DISORDERS | CHERNYSHEV, OLGA N | 1675 | §112 | Final Rejection | 28d overdue | Pending | Jul 18, 2024 |
| 18552281 | POLYPEPTIDE INHIBITORS AND USES THEREOF | LEE, JIA-HAI | 1658 | §102§112DP | Non-Final OA | — | Pending | Sep 25, 2023 |
| 18158259 | USE OF ANTI-FAM19A5 ANTIBODIES FOR TREATING CANCERS | SANG, HONG | 1646 | Other | Final Rejection | 46d | Pending | Jan 23, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNeuracle Science Co. Ltd. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Olga N Chernyshev has the most, with 1 of Neuracle Science Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
